Renal responses to long-term carotid baroreflex activation therapy in patients with drug-resistant hypertension

Hypertension

Volumn 61, Issue 6, 2013, Pages 1334-1339

  Alnima, Teba ^a   De Leeuw, Peter W ^a   Tan, Frans E S ^b   Kroon, Abraham A ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

albumin creatinine ratio; carotid baroreflex activation; drug resistant hypertension; glomerular filtration rate; renal function

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CARDIAC PATIENT; CAROTID SINUS PRESSORECEPTOR REFLEX; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART RATE; HEMODYNAMICS; HUMAN; IMPLANTATION; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

ALBUMIN/CREATININE RATIO; CAROTID BAROREFLEX ACTIVATION; DRUG-RESISTANT HYPERTENSION; GLOMERULAR FILTRATION RATE; RENAL FUNCTION;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BAROREFLEX; BLOOD PRESSURE; CAROTID ARTERIES; CREATININE; DOUBLE-BLIND METHOD; DRUG RESISTANCE; ELECTRIC STIMULATION THERAPY; ELECTRODES, IMPLANTED; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878951069     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.01159     Document Type: Article

References (35)

1. Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010; 56: 1254-1258.
2. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. Journal of the American College of Cardiology. 2011; 58: 765-773.
3. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012; 6: 152-158.
4. Cowley AW Jr. Long-term control of arterial blood pressure. Physiol Rev. 1992; 72: 231-300.
5. Tordoir JH, Scheffers I, Schmidli J, Savolainen H, Liebeskind U, Hansky B, Herold U, Irwin E, Kroon AA, de Leeuw P, Peters TK, Kieval R, Cody R. An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multi-center feasibility trial for the treatment of resistant hypertension. Eur J Vasc Endovasc Surg. 2007; 33: 414-421. (Pubitemid 46336600)
6. Illig KA, Levy M, Sanchez L, Trachiotis GD, Shanley C, Irwin E, Pertile T, Kieval R, Cody R. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg. 2006; 44: 1213-1218.
7. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; Chronic Kidney Disease Epidemiology Collaboration. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150: 604-612.
8. Tan FES. Best practices in analysis of longitudinal data: A multilevel approach. In: Osborne JW, ed. Best Practices in Quantitative Methods. California: SAGE Publications, Inc; 2007.
9. Carlini R, Obialo CI, Rothstein M. Intravenous erythropoietin (rhuepo) administration increases plasma endothelin and blood pressure in hemodialysis patients. American J Hypertens.. 1993; 6: 103-107. (Pubitemid 23080782)
10. Guyton AC. Blood pressure control-special role of the kidneys and body fluids. Science. 1991; 252: 1813-1816. (Pubitemid 21917099)
11. Guyton AC, Hall JE, Lhmeier TE, Jackson TE, Manning RD Jr. The ninth J. A. F. Stevenson memorial lecture: the many roles of the kidney in arterial pressure control and hypertension. Can J Physiol Pharmacol. 1981; 59: 513-519.
12. Lohmeier TE, Hildebrandt DA, Warren S, May PJ, Cunningham JT. Recent insights into the interactions between the baroreflex and the kidneys in hypertension. Am J Physiol Regul Integr Comp Physiol. 2005; 288: R828-R836. (Pubitemid 40404155)
13. DiBona GF. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005; 289: R633-R641.
14. DiBona GF. Neural control of the kidney: functionally specific renal sympathetic nerve fibers. Am J Physiol Regul Integr Comp Physiol. 2000; 279: R1517-R1524.
15. DiBona GF. Neural control of the kidney: past, present, and future. Hypertension. 2003; 41(3 pt 2): 621-624.
16. Lohmeier TE, Lohmeier JR, Haque A, Hildebrandt DA. Baroreflexes prevent neurally induced sodium retention in angiotensin hypertension. Am J Physiol Regul Integr Comp Physiol. 2000; 279: R1437-R1448.
17. DiBona GF. The sympathetic nervous system and hypertension: recent developments. Hypertension. 2004; 43: 147-150.
18. Lohmeier TE, Iliescu R, Dwyer TM, Irwin ED, Cates AW, Rossing MA. Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex. Am J Physiol Heart Circ Physiol. 2010; 299: H402-H409.
19. Lohmeier TE, Irwin ED, Rossing MA, Serdar DJ, Kieval RS. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension. 2004; 43: 306-311. (Pubitemid 38174130)
20. Lohmeier TE, Iliescu R. Chronic lowering of blood pressure by carotid baroreflex activation: mechanisms and potential for hypertension therapy. Hypertension. 2011; 57: 880-886.
21. Lohmeier TE, Iliescu R. Lowering of blood pressure by chronic suppression of central sympathetic outflow: insight from prolonged baroreflex activation. J Appl Physiol. 2012; 113: 1652-1658.
22. Lohmeier TE, Hildebrandt DA, Dwyer TM, Iliescu R, Irwin ED, Cates AW, Rossing MA. Prolonged activation of the baroreflex decreases arterial pressure even during chronic adrenergic blockade. Hypertension. 2009; 53: 833-838.
23. Lohmeier TE, Iliescu R, Liu B, Henegar JR, Maric-Bilkan C, Irwin ED. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension. 2012; 59: 331-338.
24. Iliescu R, Irwin ED, Georgakopoulos D, Lohmeier TE. Renal responses to chronic suppression of central sympathetic outflow. Hypertension. 2012; 60: 749-756.
25. Ditscherlein G. Renal histopathology in hypertensive diabetic patients. Hypertension. 1985; 7(6 pt 2): II29-II32.
26. Palmer BF. Impaired renal autoregulation: implications for the genesis of hypertension and hypertension-induced renal injury. Am J Med Sci. 2001; 321: 388-400. (Pubitemid 33753077)
27. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med. 2002; 347: 1256-1261. (Pubitemid 35176246)
28. Siewert-Delle A, Ljungman S, Hartford M, Wikstrand J. Effect of 14 years of antihypertensive treatment on renal function and urinary albumin excretion in primary hypertension. Am J Hypertens. 1996; 9: 841-849. (Pubitemid 26375945)
29. Ruggenenti P, Remuzzi G. Dealing with renin-angiotensin inhibitors, don't mind serum creatinine. Am J Nephrol. 2012; 36: 427-429.
30. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000; 160: 685-693. (Pubitemid 30140419)
31. Hirsch S, Hirsch J, Bhatt U, Rovin BH. Tolerating increases in the serum creatinine following aggressive treatment of chronic kidney disease, hypertension and proteinuria: pre-renal success. Am J Nephrol. 2012; 36: 430-437.
32. Mahfoud F, Cremers B, Janker J, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012; 60: 419-424.
33. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003; 348: 2285-2293. (Pubitemid 36638102)
34. Mogensen CE, Chachati A, Christensen CK, Close CF, Deckert T, Hommel E, Kastrup J, Lefebvre P, Mathiesen ER, Feldt-Rasmussen B, Schmitz A, Viberti GC. Microalbuminuria: An early marker of renal involvement in diabetes. Uremia Invest. 1985; 9: 85-95. (Pubitemid 16039450)
35. De Silva L, Weir MR. Renin inhibition and microalbuminuria development: meaningful predictor of kidney disease progression. Curr Opin Nephrol Hypertens. 2010; 19: 437-443.